Horizon Pharma PLC (NASDAQ: HZNP) released its most recent quarterly earnings report before the markets opened on Monday. The firm said that it had $0.41 in earnings per share (EPS) and $289.5 million in revenue, compared with consensus estimates that called for $0.10 in EPS and revenue of $237 million. The same period of last year reportedly had EPS of $0.56 and $257.38 million in revenue.
During the second quarter, net sales of Horizon Pharma’s medicines for rare diseases increased 70% compared to last year. Also, net sales for rare disease medicines represented 55% of total net sales, up from 36% from the second quarter of 2016.
At the same time, Horizon Pharma completed its acquisition of River Vision and its biologic, teprotumumab. Teprotumumab is in late-stage development to treat thyroid eye disease, a rare, debilitating and painful condition with no current FDA-approved therapy.
In terms of the outlook for the full year, the company increased its guidance of net sales to the range of $1.01 billion to $1.02 billion and EBITDA to $340 million to $315 million. The previous ranges were net sales of $985 million to $1.02 billion and $315 million to $350 million in EBITDA.
The consensus estimates are $0.82 in EPS and $991.23 million in revenue for the full year.
Cash and cash equivalents totaled $561.5 million at the end of the quarter, compared with $516.1 million at the end of the previous fiscal year.
Timothy P. Walbert, board chair, president and chief executive, commented:
Our rare disease medicines generated another quarter of strong performance, increasing 70 percent versus a year ago. As a result of strong second-quarter performance across our business units, we are raising our full-year sales and adjusted EBITDA guidance.
Shares of Horizon Pharma were last seen up over 6% at $13.47, with a consensus analyst price target of $15.73 and a 52-week range of $9.45 to $23.44.
It’s Your Money, Your Future—Own It (sponsor)
Are you ahead, or behind on retirement? For families with more than $500,000 saved for retirement, finding a financial advisor who puts your interest first can be the difference, and today it’s easier than ever. SmartAsset’s free tool matches you with up to three fiduciary financial advisors who serve your area in minutes. Each advisor has been carefully vetted and must act in your best interests. Start your search now.
If you’ve saved and built a substantial nest egg for you and your family, don’t delay; get started right here and help your retirement dreams become a retirement reality.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.